Generation Bio Inc. (GBIO): Price and Financial Metrics
GBIO Price/Volume Stats
| Current price | $2.98 | 52-week high | $6.98 |
| Prev. close | $3.13 | 52-week low | $0.86 |
| Day low | $2.85 | Volume | 221,100 |
| Day high | $3.15 | Avg. volume | 274,976 |
| 50-day MA | $2.97 | Dividend yield | N/A |
| 200-day MA | $3.01 | Market Cap | 198.10M |
GBIO Stock Price Chart Interactive Chart >
Generation Bio Inc. (GBIO) Company Bio
Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Latest GBIO News From Around the Web
Below are the latest news stories about GENERATION BIO CO that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
Charles Rowland Bought 179% More Shares In Generation BioPotential Generation Bio Co. ( NASDAQ:GBIO ) shareholders may wish to note that the Independent Director, Charles... |
Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)In a notable insider transaction, Rowland Charles A Jr, a director at Generation Bio Co, has significantly increased his stake in the company. |
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA PlatformsCompany to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge |
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N |
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP PlatformFigure 1 mRNA expression with T cell ctLNP in humanized mouse model Figure 2 Dose response with T cell ctLNP in humanized mouse model Figure 3a Half-life of stealth LNP in NHPs and mice Figure 3b Biodistribution of stealth LNP in NHPs 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolon |
GBIO Price Returns
| 1-mo | 0.34% |
| 3-mo | 72.25% |
| 6-mo | 166.07% |
| 1-year | -33.92% |
| 3-year | -89.67% |
| 5-year | N/A |
| YTD | 80.61% |
| 2023 | -58.02% |
| 2022 | -44.49% |
| 2021 | -75.03% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...